Developer docs
API playgroundTry for free, no card

Search company profiles

Hugel Control

Full company profile

uuid000597e

Namestring
Hugel Control
Legal namestring
Hugel Inc.
Websiteurl
hugel.co.kr
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Hugel Inc. is a South Korean bio-pharmaceutical company specializing in medical aesthetics products, principally botulinum toxin and dermal fillers. Founded in 2001 (firmographics) / 2009 (company history), the company is publicly traded on KOSDAQ under ticker 145020 and headquartered in South Korea with 501-1000 employees. Its flagship product, Letybo (letibotulinumtoxinA-wlbg), received FDA approval in 2024, making it only the 6th neuromodulator to receive FDA clearance in over 20 years and giving Hugel regulatory approvals in the three largest botulinum toxin markets (U.S., China, Europe). The product portfolio also includes dermal fillers, CellREDM (an ECM-based injectable for skin regeneration distributed through a partnership with Hans Biomed in South Korea), and BYRYZN BR, a premium dermocosmetics brand launched in China.

The company operates a hybrid go-to-market model combining distributor partnerships with direct sales. In the U.S., BENEV Company handles commercialization of Letybo; in South Korea, Hans Biomed distributes CellREDM. Hugel employs a multi-channel marketing approach centered on industry conferences (AMWC KOREA, J.P. Morgan Healthcare Conference), the L.E.A.D. education program featuring live demonstrations, and global networking events with healthcare professionals. Pricing is structured to be cost-competitive against incumbent Botox: Letybo launched in the U.S. at approximately USD 7 per unit versus Botox at ~USD 15 per unit.

FY2025 net sales reached KRW 425.1 billion (+14% YoY), with Q1 2026 net sales of KRW 116.6 billion (+29.9% YoY). The company has set a 2028 sales target of KRW 900 billion with over 30% from the U.S. market. Products are distributed across 65 countries with over 31 million successful treatments recorded globally. Leadership is headed by Carrie Strom as President and Global CEO.

Short descriptiontext

Hugel Inc. is a South Korean bio-pharmaceutical company that develops and commercializes medical aesthetics products, including FDA-approved botulinum toxin (Letybo), dermal fillers, ECM-based injectables (CellREDM), and dermocosmetics (BYRYZN BR), serving healthcare professionals and aesthetic clinics across 65 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersChuncheon, South Korea
HQ citystring
Chuncheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
botulinum toxin products, dermal fillers, medical aesthetics, injectable treatments, cosmetic pharmaceuticals
Industry3 codes
PRIMARYHLAKACAE
Cosmetic Dermatology (Aesthetic Injectables)
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Perfumes, Cosmetics & Other Toilet Preparations2844
Product category
Medical Aesthetics Pharmaceuticals
No data
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Botulinum Toxin Products
TypeOne Time License
Description

Primary revenue driver with botulinum toxin sales growing 60.6% year-on-year to KRW 65.4 billion in Q1 2026. Products include Letybo and Botuligin Capture EX Ampoule.

prnewswire.com
2Dermal Fillers
TypeOne Time License
Description

Dermal filler products contributing to strong global demand alongside botulinum toxin products. Export share rising from 66% in 2024 to 74% in 2025.

morningstar.com
3ECM-based Injectables
TypeOne Time License
Description

CellREDM distributed through partnership with Hans Biomed, expanding portfolio into skin regeneration treatments.

prnewswire.com
4Dermocosmetics (BYRYZN BR)
TypeOne Time License
Description

Premium dermocosmetics brand launched in China, starting with Botuligin Capture EX Ampoule, with plans to introduce four more products under the line.

koreabiomed.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Marketing or Sales, Technology or R&D, Personnel
Pricing details1 tier
1Letybo (letibotulinumtoxinA) - competitive pricing vs Botox
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Launched in US at approximately USD 7 per unit vs BOTOX at ~USD 15 per unit (USD 525 for 35 units)

grandviewresearch.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Letybo (letibotulinumtoxinA)
Description

FDA-approved botulinum toxin product for treating glabellar lines

iconiclaser.com
+2 more records
Core offering1 text field

Hugel Inc. develops, manufactures, and commercializes medical aesthetics products including FDA-approved botulinum toxin (Letybo/letibotulinumtoxinA), dermal fillers, ECM-based injectables for skin regeneration (CellREDM), and premium dermocosmetics (BYRYZN BR). The company sells these products globally to healthcare professionals and aesthetic clinics across the U.S., China, Europe, Brazil, the Middle East, and other markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 31+ million successful treatments recorded globally across 65 countries
+3 more records
Product overview1 text field

Hugel is a South Korean medical aesthetics company offering a portfolio of botulinum toxin products (Letybo), dermal fillers, and ECM-based injectables (CellREDM). The company also expanded into premium dermocosmetics with the BYRYZN BR brand. Hugel's products are distributed globally across the U.S., China, Europe, and other markets, with the company targeting KRW900 billion in annual sales by 2028.

Product and service4 records
1Letybo (letibotulinumtoxinA)
CategoryBotulinum Toxin
Description

FDA-approved botulinum toxin product for treating glabellar lines (frown lines). Sold to medical aesthetic practitioners and clinics as a competitively priced neuromodulator.

2Dermal Fillers
CategoryDermal Fillers
Description

Hugel's dermal filler products for facial aesthetics procedures, contributing to overseas sales growth alongside botulinum toxin products. Sold to aesthetic clinics and practitioners.

3CellREDM
CategoryECM-based Injectables
Description

ECM (extracellular matrix)-based injectable product for skin regeneration treatments. Distributed in South Korea through partnership with Hans Biomed.

4BYRYZN BR (incl. Botuligin Capture EX Ampoule)
CategoryDermocosmetics
Description

Premium dermocosmetics brand launched in China for the high-end skin care market, starting with the Botuligin Capture EX Ampoule for anti-aging.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-31
Description

Hugel secured domestic sales rights for CellREDM and formed a distribution partnership with Hans Biomed in South Korea. The collaboration aims to enhance Hugel's aesthetic product portfolio and leverage synergies with existing offerings, targeting accelerated market penetration into ECM-based injectable market.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-25
Description

BENEV Company and Hugel announced full U.S. commercialization of Letybo through their partnership. Letybo became only the 6th neuromodulator to receive FDA approval in over 20 years, with over 31 million successful treatments recorded globally across 65 countries. The collaboration leverages BENEV's U.S. market presence and Hugel's position as the only South Korean company with regulatory approvals in the three largest botulinum toxin markets.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hugel Control

Medical Aesthetics Pharmaceuticalshugel.co.kr

Hugel Inc. is a South Korean bio-pharmaceutical company that develops and commercializes medical aesthetics products, including FDA-approved botulinum toxin (Letybo), dermal fillers, ECM-based injectables (CellREDM), and dermocosmetics (BYRYZN BR), serving healthcare professionals and aesthetic clinics across 65 countries.

What Hugel Control does

Hugel Inc. is a South Korean bio-pharmaceutical company specializing in medical aesthetics products, principally botulinum toxin and dermal fillers. Founded in 2001 (firmographics) / 2009 (company history), the company is publicly traded on KOSDAQ under ticker 145020 and headquartered in South Korea with 501-1000 employees. Its flagship product, Letybo (letibotulinumtoxinA-wlbg), received FDA approval in 2024, making it only the 6th neuromodulator to receive FDA clearance in over 20 years and giving Hugel regulatory approvals in the three largest botulinum toxin markets (U.S., China, Europe). The product portfolio also includes dermal fillers, CellREDM (an ECM-based injectable for skin regeneration distributed through a partnership with Hans Biomed in South Korea), and BYRYZN BR, a premium dermocosmetics brand launched in China.

The company operates a hybrid go-to-market model combining distributor partnerships with direct sales. In the U.S., BENEV Company handles commercialization of Letybo; in South Korea, Hans Biomed distributes CellREDM. Hugel employs a multi-channel marketing approach centered on industry conferences (AMWC KOREA, J.P. Morgan Healthcare Conference), the L.E.A.D. education program featuring live demonstrations, and global networking events with healthcare professionals. Pricing is structured to be cost-competitive against incumbent Botox: Letybo launched in the U.S. at approximately USD 7 per unit versus Botox at ~USD 15 per unit.

FY2025 net sales reached KRW 425.1 billion (+14% YoY), with Q1 2026 net sales of KRW 116.6 billion (+29.9% YoY). The company has set a 2028 sales target of KRW 900 billion with over 30% from the U.S. market. Products are distributed across 65 countries with over 31 million successful treatments recorded globally. Leadership is headed by Carrie Strom as President and Global CEO.

Hugel Control firmographics

Firmographics
Name
Hugel Control
Legal name
Hugel Inc.
Website
https://hugel.co.kr
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Hugel Inc. is a South Korean bio-pharmaceutical company that develops and commercializes medical aesthetics products, including FDA-approved botulinum toxin (Letybo), dermal fillers, ECM-based injectables (CellREDM), and dermocosmetics (BYRYZN BR), serving healthcare professionals and aesthetic clinics across 65 countries.
Ownership category
akta.pro rank

Hugel Control industry classification

Industry
Product category
Medical Aesthetics Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Perfumes, Cosmetics & Other Toilet Preparations (2844)
akta.pro industry
PRIMARYHLAKACAE
Cosmetic Dermatology (Aesthetic Injectables)
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare

Keywords

  • Botulinum toxin products
  • Dermal fillers
  • Medical aesthetics
  • Injectable treatments
  • Cosmetic pharmaceuticals

Where Hugel Control is headquartered

Location

Headquarters

HQ city
Chuncheon
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Hugel Control business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Marketing or Sales, Technology or R&D, Personnel

Revenue model

  1. Botulinum Toxin Products: Primary revenue driver with botulinum toxin sales growing 60.6% year-on-year to KRW 65.4 billion in Q1 2026. Products include Letybo and Botuligin Capture EX Ampoule.
  2. Dermal Fillers: Dermal filler products contributing to strong global demand alongside botulinum toxin products. Export share rising from 66% in 2024 to 74% in 2025.
  3. ECM-based Injectables: CellREDM distributed through partnership with Hans Biomed, expanding portfolio into skin regeneration treatments.
  4. Dermocosmetics (BYRYZN BR): Premium dermocosmetics brand launched in China, starting with Botuligin Capture EX Ampoule, with plans to introduce four more products under the line.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goLetybo (letibotulinumtoxinA) - competitive pricing vs Botox

Go-to-market motion4 records

Distribution channels4 records

Marketing channels4 records

Hugel Control product offering

Product offering

Core offering

Hugel Inc. develops, manufactures, and commercializes medical aesthetics products including FDA-approved botulinum toxin (Letybo/letibotulinumtoxinA), dermal fillers, ECM-based injectables for skin regeneration (CellREDM), and premium dermocosmetics (BYRYZN BR). The company sells these products globally to healthcare professionals and aesthetic clinics across the U.S., China, Europe, Brazil, the Middle East, and other markets.

Product overview

Hugel is a South Korean medical aesthetics company offering a portfolio of botulinum toxin products (Letybo), dermal fillers, and ECM-based injectables (CellREDM). The company also expanded into premium dermocosmetics with the BYRYZN BR brand. Hugel's products are distributed globally across the U.S., China, Europe, and other markets, with the company targeting KRW900 billion in annual sales by 2028.

Differentiator

Problem solved

Functional benefit

Brands

  • Letybo (letibotulinumtoxinA): FDA-approved botulinum toxin product for treating glabellar lines
  • BYRYZN BR
  • CellREDM

Products and services

  • Letybo (letibotulinumtoxinA) FDA-approved botulinum toxin product for treating glabellar lines (frown lines). Sold to medical aesthetic practitioners and clinics as a competitively priced neuromodulator.
  • Dermal Fillers Hugel's dermal filler products for facial aesthetics procedures, contributing to overseas sales growth alongside botulinum toxin products. Sold to aesthetic clinics and practitioners.
  • CellREDM ECM (extracellular matrix)-based injectable product for skin regeneration treatments. Distributed in South Korea through partnership with Hans Biomed.
  • BYRYZN BR (incl. Botuligin Capture EX Ampoule) Premium dermocosmetics brand launched in China for the high-end skin care market, starting with the Botuligin Capture EX Ampoule for anti-aging.

Quantifiable outcome

  • 31+ million successful treatments recorded globally across 65 countries
  • +3 more outcomes

Companies that use Hugel Control

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Hugel Control technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Hugel Control partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Hans BiomedcoreChannel Partner/ Reseller/ Distributor · 31 March 2026Hugel secured domestic sales rights for CellREDM and formed a distribution partnership with Hans Biomed in South Korea. The collaboration aims to enhance Hugel's aesthetic product portfolio and leverage synergies with existing offerings, targeting accelerated market penetration into ECM-based injectable market.
  • BENEV Company, Inc.coreChannel Partner/ Reseller/ Distributor · 25 March 2025BENEV Company and Hugel announced full U.S. commercialization of Letybo through their partnership. Letybo became only the 6th neuromodulator to receive FDA approval in over 20 years, with over 31 million successful treatments recorded globally across 65 countries. The collaboration leverages BENEV's U.S. market presence and Hugel's position as the only South Korean company with regulatory approvals in the three largest botulinum toxin markets.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Hugel Control competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Hugel Control financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hugel Control leadership team

Management profile

Number of profiles

Profiles7 records

Hugel Control funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hugel Control M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hugel Control

What does Hugel Control do?

Hugel Inc. develops, manufactures, and commercializes medical aesthetics products including FDA-approved botulinum toxin (Letybo/letibotulinumtoxinA), dermal fillers, ECM-based injectables for skin regeneration (CellREDM), and premium dermocosmetics (BYRYZN BR). The company sells these products globally to healthcare professionals and aesthetic clinics across the U.S., China, Europe, Brazil, the Middle East, and other markets.

Is Hugel Control a public or private company?

Hugel Control is a public company. It is classified as public and is currently operating.

When was Hugel Control founded?

Hugel Control was founded in 2009. It employs 501 to 1,000 people.

Where is Hugel Control based?

Hugel Control is headquartered in Chuncheon, South Korea, in the Asia region.

How does Hugel Control make money?

Four revenue lines are on record. Botulinum Toxin Products are the primary driver. The others are dermal Fillers, ECM-based Injectables and dermocosmetics (BYRYZN BR).

Does Hugel Control have an API?

No public API is recorded for Hugel Control.

What industry is Hugel Control in?

Hugel Control's product category is Medical Aesthetics Pharmaceuticals. Its primary akta.pro industry code is HLAKACAE, Cosmetic Dermatology (Aesthetic Injectables), with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingHugel’s nine-month sales rise 15% on strong Korea, Europe demandHugel reported a 15% revenue increase to 352.1 billion won for the first nine months of 2026, driven by strong sales of botulinum toxin, fillers, and skin boosters in Korea and Europe. Q3 revenue was 97.5 billion won, with net profit of 4.7 billion won. The company expects the new U.S. distribution model to strengthen its Letybo brand.PRESSBEEHugel reports Q1-Q3 net sales of KRW352.1 billion, up 15% year-on-year ...Middle EastHugel reported Q1-Q3 net sales of KRW352.1 billion, up 15% year-on-year, with Q3 sales reaching KRW97.5 billion. The surge was driven by U.S. sales model changes, with combined botulinum toxin, HA fillers, and skinboosters sales rising 54% in Korea and 18% in Europe and other regions.EIN PresswireHugel introduces visiting doctors to Korean aestheticsHugel hosted its Aesthetic Excellence Summit 2026, bringing 20 medical professionals from multiple regions for hands-on training in cosmetic procedures. The summit covered botulinum toxin and dermal filler production, anatomy, and injection techniques, with Hugel's executive vice president promising continued international outreach.NaverHugel introduces visiting doctors to Korean aestheticsHugel hosted its Aesthetic Excellence Summit 2026, bringing 20 medical professionals from Europe, Asia, the Middle East, and South America for hands-on training in cosmetic procedures. The summit covered botulinum toxin and dermal filler production, anatomy-guided injection techniques, and facial injection protocols. Hugel's executive vice president said the company will continue introducing international practitioners to K-aesthetics.EIN PresswireHugel introduces visiting doctors to Korean aestheticsHugel hosted its Aesthetic Excellence Summit 2026, bringing 20 medical professionals from multiple regions for hands-on training in cosmetic procedures. The summit covered botulinum toxin and dermal filler production, anatomy, and injection techniques, with Hugel's executive vice president promising continued international outreach.The Korea HeraldHugel introduces visiting doctors to Korean aestheticsHugel hosted its Aesthetic Excellence Summit 2026, bringing 20 medical professionals from Europe, Asia, the Middle East, and South America for hands-on training in cosmetic procedures. The summit covered botulinum toxin and dermal filler production, anatomy-guided injection techniques, and facial injection protocols. Hugel's executive vice president said the company will continue introducing international practitioners to K-aesthetics.EIN PresswireBotulinum Toxin Market to reach USD 32.48 Billion by 2035 at 9.15% CAGRThe global botulinum toxin market is projected to grow from USD 13.50 billion in 2025 to USD 32.48 billion by 2035, a 9.15% CAGR. Growth is driven by reimbursed therapeutic indications, rising aesthetic procedures, and ready-to-use liquid formulations. North America holds 39.6% of 2025 revenue, with Asia-Pacific expected to compound at 12.9% through 2035.NateHugel approves the plan to utilize treasury shares at the temporary general meeting... 'Reflecting the amended Commercial Act': Nate NewsHugel approved a plan to utilize treasury shares for employee performance compensation and key talent retention at its temporary shareholders' meeting in Chuncheon. The company also passed resolutions regarding stock options for key employees and governance enhancements, including the separate election of independent directors for the audit committee in compliance with the revised Commercial Act.The Korea HeraldHugel’s Wellage lands at Sephora USWellage, a clinical cosmetics brand owned by Hugel, has launched in Sephora stores across the US in partnership with Olive Young, expanding its market presence. The initial launch features five products from the Real Hyaluronic line and includes a mobile pop-up campaign visiting Sephora locations in New York, Texas, and Florida. Hugel aims to strengthen the presence of K-beauty in the US and globally.Third NewsHugel Partners with OLIVE YOUNG to Launch WELLAGE at Sephora US, Expanding Global SkincareHugel Inc. has partnered with OLIVE YOUNG to launch its WELLAGE skincare line at Sephora US stores starting August 20, 2026. The collaboration includes in-store displays and pop-up events in major U.S. cities to capitalize on the growing demand for Korean beauty products in North America.